September 16, 2019Open Access

Multicenter Prospective Study of the Efficacy and Safety of Combined Immunosuppressive Therapy With High‐Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Diseases Accompanied by Anti–Melanoma Differentiation–Associated Gene 5–Positive Dermatomyositis

Key Points

Key points are not available for this paper at this time.

Abstract

A combined immunosuppressive regimen is effective for anti-MDA-5-positive DM patients with ILD. Plasmapheresis can be used for additional effect in intractable disease. Patients should be carefully monitored for opportunistic infections during treatment.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

Tsuji et al. (Mon,) studied this question.

synapsesocial.com/papers/69d9455c00ab073a27835a47 — DOI: https://doi.org/10.1002/art.41105

Authors

Hideaki Tsuji

Kyoto University

Ran Nakashima

Kyoto University

Yuji Hosono

Iwate Medical University

Journals

Arthritis & Rheumatology

Actions

Institutions

Kyoto University

National Institute of Arthritis and Musculoskeletal and Skin Diseases

Hiroshima University Hospital

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Multicenter Prospective Study of the Efficacy and Safety of Combined Immunosuppressive Therapy With High‐Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Diseases Accompanied by Anti–Melanoma Differentiation–Associated Gene 5–Positive Dermatomyositis

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Cite this study

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion